Multiple System Atrophy (MSA) is a rare, rapidly progressive neurodegenerative disorder characterised by a combination of parkinsonism, cerebellar ataxia and autonomic dysfunction. Clinical assessment ...

Multiple system atrophy (MSA) is a relentlessly progressive adult-onset synucleinopathy characterised by the intracytoplasmic accumulation of α-synuclein in oligodendrocytes, manifesting as glial ...

Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

Multiple system atrophy is a rare and fatal neurodegenerative disease, where insoluble inclusions of the protein alpha-synuclein appear in oligodendrocyte cells of the brain. The resulting ...

Researchers from the Florey Institute of Neuroscience and Mental Health have advanced understanding of the biological mechanisms underlying a rare neurological disease called Multiple System Atrophy ...

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

The developer of a drug for the rare multiple system atrophy, Alterity will launch a pivotal phase III trial after a go-ahead ...

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol - - FDA agreed that a single pivotal Phase 3 trial ...

MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

Detailed price information for Alterity Therapeutics Ltd ADR (ATHE-Q) from The Globe and Mail including charting and trades.